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Background
Human 4E10 is one of the broadest-specificity, HIV-1
neutralizing, monoclonal antibodies described to date,
recognizing a linear, membrane-proximal epitope on
gp41. Although the apparent rarity of 4E10-like antibody
responses in HIV infections is suggested to result from
their elimination through B cell tolerance mechanisms to
self-antigens, the lipid cross-reactivity of 4E10 has also
been suggested to derive from virus-specific membrane
binding outside of the MPER, rather than auto-reactivity,
that contributes to neutralization potency.
Methods
To investigate how 4E10 interacts with membrane com-
ponents (particularly phospholipids like cardiolipin), and
whether such interactions contribute to neutralization
mechanisms, we have introduced two mutations into
4E10 Fv constructs: W(H100)A and G(L50)E. The binding
of 4E10 and these mutants to liposomes of varying com-
position, to 4E10 epitope peptides and to soluble mono-
meric and trimeric HIV Env gp140 was then assayed by
surface plasmon resonance.
Results
These analyses revealed that wild type and mutant 4E10
Fvs all bind with the same affinity to epitope peptides and
monomeric and trimeric gp140s, but that the affinities for
gp140s are uniformly ten-fold weaker than to peptides.
Addition of cardiolipin to liposomes increases wild-type,
but not mutant, 4E10 Fv SPR binding responses, suggest-
ing that the mutations individually and cleanly attenuate
specific 4E10/lipid interactions. However, 4E10 Fv bind-
ing to lipid bilayers of any composition is extremely weak.
While the W(H100)A affects neutralization significantly,
the G(L50)E mutation, selected to disrupt a possible
phosphate-binding site on 4E10, does not decrease neu-
tralization efficiency against diverse HIV-1 isolates.
Conclusion
This dichotomy suggests that specific lipid interactions
and neutralization by 4E10 are formally separable. Addi-
tional EPR experiments suggest an alternate explanation
for the effect of the W(H100)A on neutralization: this
mutation reduces the ability of 4E10 to wedge the MPER
out of the membrane.
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